anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will sign an informed consent and assent to participate. Skin and both nares will be cultured for S aureus. A blood sample and two 2 mm skin biopsies will be obtained one from non-lesional skin and another one from lesional skin). The patients will be instructed in the use of the three-week S. aureus decolonization regimen and provided with the medications (sulfamethoxazole/trimethoprim and Mupirocin ointment) and Chlorhexidine. The second visit will take place immediately at the end of the three-week S. aureus skin decolonization regimen. Disease severity will be assessed, the skin and nares will be re-cultured, and skin biopsies and blood will be obtained.
OBJECTIVE: Parkinson disease (PD) is associated with a predictable decline in motor function and mobility that is commonly managed with exercise. There is a limited understanding of the effects of group exercise compared to individual exercise (IE) and usual care (UC) on motor function and mobility. Our purpose was to investigate the effects of group exercise compared to IE and UC on motor function and mobility for people with PD.
METHODS: A systematic review and meta-analysis was performed with randomized control trials that investigated the effects of group compared with IE and UC on motor function and mobility for people with PD. A systematic search was performed in PubMed, EBSCO, and Science Direct databases. Methodological quality was assessed using the Cochrane Grading of Recommendations Assessment, Development, and Evaluation approach.
RESULTS: Twenty-three studies assessed at least 1 mobility-related outcome measure, met our inclusion criteria, and were included in quantitative analysis. There was no significant difference on motor function and mobility between group exercise and IE for all standardized outcome assessment meta-analyses. Motor function and mobility were significantly improved with group exercise compared to UC in 9 of 11 standardized outcome assessment meta-analyses. Results were based upon low to moderate quality of evidence.
CONCLUSION: Based upon low to moderate quality of evidence, group exercise has a similar to larger effect as IE and UC on improving motor function and mobility for people with PD. When used in combination with skilled physical therapy, group exercise may be an appropriate adjunct to individualized physical therapy to maximize mobility and function.
IMPACT: Long-term adherence to exercise is essential to maintain mobility and motor function for people with PD. Our study suggests group exercise is as effective as IE and may be an appropriate option to encourage long-term adherence related to increased access, socialization, and accountability.
The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Neospora caninum is one of the most frequently diagnosed abortifacient pathogens in cattle. There is abundant genomic information about the parasite itself, but very little is known about the genetic variability of resistance in the most common intermediate host. The aim of this review was to compile all the available information about the genetic variability associated with the resistance to N. caninum both between and within cattle breeds. We systematically searched for published studies that investigated the influence of genetics of the host on the prevalence of N. caninum and risk of abortion. Beyond the potential confounding effects of feeding systems, management and animal density, some lines of evidence suggest that Holstein, the most popular breed for milk production, has a comparatively higher risk of abortion due to infections by N. caninum, whereas some beef breeds from Continental Europe seem to be more resistant. It is still not clear if different genetic mechanisms of resistance are involved in the two known routes of infection: postnatal ingestion of oocysts or transplacental transmission from the infected dam to the fetus. Genomic information associated with susceptibility to infection and risk of abortion in different cattle breeds is still scarce. The information reported here could be useful to identify new research alternatives and to define novel strategies to deal with this major problem of animal production.
Alternative tobacco products are becoming increasingly available in the US market and are promoted as potentially less deleterious compared to cigarettes. These products are increasing in usage as either a substitution for cigarette smoking or in addition to smoking. One particular appeal is that they often combine nicotine with sweet taste and flavors, which are themselves reinforcing. The primary goal of this project is to determine if sweet taste can potentiate the reinforcing properties of nicotine. Similar to nicotine, cues predicting the availability of carbohydrates can stimulate intake, even in the absence of hunger. The investigators have developed a novel flavor-nutrient conditioning paradigm to study the reinforcing properties of carbohydrates. Novel flavors are paired with 0 or 113 kcal carbohydrate and increases in flavor-cue reactivity (change in liking and brain response) when later sampled in the absence of the carbohydrate provide a measure of the reinforcing potency. For smokers, the aroma of tobacco is a potent cue that can promote smoking behavior. Using a modified version of our conditioning paradigm, our specific aim is to test the prediction that sweet taste perception enhances the ability of nicotine to induce neural plastic changes in brain reward circuits to increase the saliency, liking and brain reactivity to the sight and vaporized flavor of electronic cigarettes (e-cigarettes). Participants will smoke e-cigarettes that contain nicotine and an unsweetened vaporized flavor, nicotine and a sweet vaporized flavor or only a sweet vaporized flavor (no nicotine). The investigators predict that response in the nucleus accumbens and hypothalamus to the sight and vaporized flavor of the e-cigarette that was paired with nicotine and sweet taste will be greater than the responses to the sight and vaporized flavors associated with the other e-cigarettes. The investigators further predict that liking and wanting will increase more for the sight and vaporized flavor associated with both nicotine and sweet taste. This finding would provide strong evidence that sweet taste potentiates the reinforcement potency of nicotine and could therefore promote use.
Approval of the study was obtained from the hospital's ethical committee. The study design and methodology followed the tenets of Declaration of Helsinki. All patients were provided with written informed consent and received a thorough explanation of the study design, aims, and the off-label use of infliximab, its potential risks and benefits. This is a prospective non-comparative interventional study.

Participants will receive intravitreal injections of suggested dose of infliximab (5 mg/kg/dose) and data will be collected prospectively with regard to ophthalmologic outcomes. Study participants will be followed for up to 10 months to determine efficacy and side effects, and an additional 30 days for safety reports. Descriptive statistics will be gathered on participant demographics, uveitis characteristics, change in immunosuppressive medications, number of responders, ophthalmologic measures and change in corticosteroid dose during the study period.
NEW MATERIAL:An organogermanium compound expressed by formula I [R1 is lower alkyl; R2-R4 are H, lower alkyl or (substituted) phenyl; Z is carboxyl, benzylaminomethyl or hydrochloride thereof]. EXAMPLE:(n-C3H7)GeCH2CH2COOH. USE:An inhibitor against opioid hydrolyzing enzymes and analgesi capable of selectively inhibiting enzymes hydrolyzing enkephalin which is one kind of endogenous morphinic substance, e.g. aminopeptidase derived from simian brains, etc., in a low concentration. PREPARATION:For example, trichlorogermylpropionic acid expressed by formula III is reacted with a Grignard reagent expressed by the formula R1MgX in a solvent e.g. ethyl ether, etc., while heating and refluxing according to the reaction formula and the resultant product is then hydrolyzed with hydrochloric acid.
The invention relates to a medicine for regulating the blood pressure, which belongs to the field of traditional Chinese medicines. The invention aims to provide the medicine for regulating the blood pressure, which aims at a patient with mild hypertension for searching for the primary cause of a disease in treatment by adopting the theory of traditional Chinese medicine so as to together achieve the treatment effect of lowering the pressure by dredging the collaterals, removing the stasis, suppressing the excessive yang and calming vertigo. The medicine for regulating the blood pressure comprises the following raw materials for preparing effective components according to parts by weight: fructus evodiae, radix geutianae, apocynum venetum, cinnabar, alum, radix achyranthis bidentatae, ligusticum wallichii, self-heal, mugwort leaf and radix salviae miltiorrhizae. The medicine for regulating the blood pressure is simple to prepare and has low price, good curative effect, no toxic or side effect, short treatment time and good social and economic benefits. Various medicines are matched. The medicine for regulating the blood pressure aims at mild hypertension for searching for the primary cause of a disease in treatment for a patient with hypertension in head and eye vertigo, headache and a heavy feeling in the brain, which are caused by liver-fire flaming, liver-yang hyperactivity, the obstruction of the collaterals by the blood stasis and the like, so as to together achieve the treatment effect of lowering the pressure by dredging the collaterals, removing the stasis, suppressing the excessive yang and calming the vertigo.
BACKGROUND: Lower urinary tract syndrome (LUTS) is a group of urinary tract symptoms and signs that can include urinary incontinence. Advancing age is a major risk factor for LUTS; however, the underlying biochemical mechanisms of age-related LUTS remain unknown. Hypoxanthine (HX) is a purine metabolite associated with generation of tissue-damaging reactive oxygen species (ROS). This study tested the hypothesis that exposure of the adult bladder to HX-ROS over time damages key LUT elements, mimicking qualitatively some of the changes observed with aging.
METHODS: Adult 3-month-old female Fischer 344 rats were treated with vehicle or HX (10 mg/kg/day; 3 weeks) administered in drinking water. Targeted purine metabolomics and molecular approaches were used to assess purine metabolites and biomarkers for oxidative stress and cellular damage. Biomechanical approaches assessed LUT structure and measurements of LUT function (using custom-metabolic cages and cystometry) were also employed.
RESULTS: HX exposure increased biomarkers indicative of oxidative stress, pathophysiological ROS production, and depletion of cellular energy with declines in NAD+ levels. Moreover, HX treatment caused bladder remodeling and decreased the intercontraction interval and leak point pressure (surrogate measure to assess stress urinary incontinence).
CONCLUSIONS: These studies provide evidence that in adult rats chronic exposure to HX causes changes in voiding behavior and in bladder structure resembling alterations observed with aging. These results suggest that increased levels of uro-damaging HX were associated with ROS/oxidative stress-associated cellular damage, which may be central to age-associated development of LUTS, opening up potential opportunities for geroscience-guided interventions.
The present invention features a method of making a gel cosmetic stick. The method comprises first mixing a particulate dibenzylidene alditol with a liquid vehicle which contains an antiperspirant salt dissolved therein to form a uniform dispersion. The dibenzylidene alditol is mixed with the liquid vehicle at a temperature sufficiently low, preferably below 50 DEG  C., so that substantially none of the dibenzylidene alditol dissolves in the liquid vehicle. This dispersion may comprise a commercial size quantity, typically greater than 200 kg. A portion of this dispersion, typically a relatively small portion, is then heated to a temperature sufficient to dissolve the dibenzylidene alditol therein, then cooled to form a gel. This heating and cooling is conducted sufficiently rapidly so as to minimize degradation of the dibenzylidene alditol. Preferably the heating and cooling is conducted such that said portion is subjected to a temperature greater than 90 DEG  C. for not more than two hours, most preferably not more than thirty minutes.
This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
OBJECTIVE: To analyze whether infants admitted to hospital with Acute Viral Bronchiolitis (AVB), who received glucocorticoids and bronchodilators, and who had an atopic phenotype, spent less time in hospital and/or less time on oxygen therapy when compared to those who did not have the phenotype.
METHOD: A cross-sectional, retrospective epidemiological study was developed with data from medical records of infants admitted to hospital due to AVB from 2012 to 2019 in a sentinel public hospital. It was verified that the frequency of prescription of glucocorticoids, bronchodilators and antibiotics. Length of stay and oxygen therapy duration were then compared in the group that used glucocorticoids and bronchodilators between those who had a personal or family history of atopy and those who did not. Subsequently, the length of hospital stay was compared among infants who received antibiotic therapy and those who did not.
RESULTS: Fifty-eight infants were included. Of these, 62.1 % received an antibiotic, 100 % a bronchodilator and 98.3 % a glucocorticoid. When comparing infants without a family history of atopy, those who received antibiotics had a longer hospital stay (p = 0.01).
CONCLUSION: The presence of an atopic phenotype did not interfere with the length of stay and/or oxygen therapy duration of those who received bronchodilators and glucocorticoids. Increased length of stay of infants without a family history of atopy, who used antibiotics without evidence of bacterial co-infection, and the high frequency of prescription of non-recommended drugs call attention to stricter protocol implementation and professional training in AVB diagnosis and care.
The invention discloses compounds and an application thereof in preparation of anti-parasitosis drugs. The compounds have a structural formula represented by the formula I or the formula II. The compounds provided by the invention have rich functional group diversity and modificability, and the products are relatively easy to separate and purify. The compounds provided by the invention have quite good inhibitory effect on pernicious malaria NDH protein activity and are new anti-malarial action targets and mechanisms, and thus the compounds also have quite good inhibitory effect on many plasmodium species and strains generating resistance to traditional drugs, thereby providing a new breakthrough for current increasingly-serious plasmodium drug resistance aspect. At the same time, the plasmodium NDH and human NADH oxidordeuctase belong to different species, so that the compounds can be expected to produce fewer side effects on human. In summary, the compounds have broad development and application prospects.
Premature Ovarian Insufficiency (POI) is a highly heterogeneous condition characterized by ovarian dysfunction in women occurring before the age of 40, representing a significant cause of female infertility. It manifests through primary or secondary amenorrhea. While more than half of POI cases are idiopathic, genetic factors play a pivotal role in all instances with known causes, contributing to approximately 20-25% of cases. This article comprehensively reviews the genetic factors associated with POI, delineating the primary candidate genes. The discussion delves into the intricate relationship between these genes and ovarian development, elucidating the functional consequences of diverse mutations to underscore the fundamental impact of genetic effects on POI. The identified genetic factors, encompassing gene mutations and chromosomal abnormalities, are systematically classified based on whether the resulting POI is syndromic or non-syndromic. Furthermore, this paper explores the genetic interplay between mitochondrial genes, such as Required for Meiotic Nuclear Division 1 homolog Gene (RMND1), Mitochondrial Ribosomal Protein S22 Gene (MRPS22), Leucine-rich Pentapeptide Repeat Gene (LRPPRC), and non-coding RNAs, including both microRNAs and Long non-coding RNAs, with POI. The insights provided serve to consolidate and enhance our understanding of the etiology of POI, contributing to establishing a theoretical foundation for diagnosing and treating POI patients, as well as for exploring the mechanisms underlying the disease.
BACKGROUND AND OBJECTIVES: Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability progression (CDP) in a cohort of patients with PPMS treated with anti-CD20 therapies compared with a weighted untreated control cohort.
METHODS: This was a retrospective study using data from the French MS registry (Observatoire Français de la Sclérose En Plaques). We included patients with PPMS treated or never treated with anti-CD20 therapies from 2016 to 2021, with an Expanded Disability Status Scale score of ≤6.5 at baseline. The primary outcome was time to first CDP. The secondary outcomes were time to first relapse, MRI activity at 2 years, identification of risk factors associated with CDP, and serious infection incidence rates (IIRs). Each outcome was studied using an inverse probability of treatment weighting method. The outcomes were modeled using a weighted proportional Cox model for the time-to-event outcomes and by a logistic regression regarding the MRI activity.
RESULTS: A total of 1,184 patients (426 treated and 758 untreated) fulfilled the inclusion criteria. Median age (Q1-Q3) was 56 years (49.3-63.8), and 52.7% were female. Among treated patients, 295 received rituximab, whereas 131 received ocrelizumab. At baseline, anti-CD20-treated patients were younger (median 51.9 vs 58.6 years, Cohen d = 0.683) and had more active disease (54.5 vs 27.8%, Cohen d = 0.562). 91.6% were drug-naive at inclusion. In time to first CDP analysis, no statistical significance was observed (hazard ratio [HR], 1.13; 95% CI 0.93-1.36, p = 0.2113). In time to first relapse analysis, a nonsignificant trend toward fewer patients relapsing in the treated group was observed (HR 0.83; 95% CI 0.48-1.28, p = 0.0809). For MRI activity, no significant difference was found between the 2 groups. Risk factors associated with CDP in the treated group were male sex and MS duration. IIR was 6.67 (95% CI 3.12-14.25) per 100 person-years in the treated group vs 2.67 (95% CI 0.80-8.86) in the untreated group.
DISCUSSION: Time to first CDP was not different between anti-CD20 treated and untreated patients with PPMS. Although our study is retrospective and mainly included patients treated by rituximab, our results indicate that there should be a constant evaluation of all available data to ascertain the best risk/benefit ratio for patients with PPMS.
CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that anti-CD20 therapy of previously untreated patients with PPMS was not superior to no therapy in delaying time to first CDP.
In the second experimental group, kaleidoscope was used to distract attention. A kaleidoscope, or kaleidoscope, is a device that sees colorful patterns when looked into. Inside, there are three mirrors adjacent to each other with an inclination of 60 degrees between them. There are pieces of colored glass between the mirrors. When viewed from one end of this binocular, shape-shifting polygons are seen, often with images that will never be the same again. These patterns are created by the reflection of light and change constantly as the binoculars are moved.
A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
PURPOSE: To prepare baby powder containing an extract having excellent deodorizing effect on body-smell by synergistic action of various components, by extracting tea such as green tea or red tea with methanol or water. CONSTITUTION: Green team red tea, oolong or Paraguay tea as a raw material is extracted with hot water or an extracting solvent such as methanol, ethanol, propanol, isopropanol, methyl ethyl ketone, acetone or ethyl acetate. Then the solvent is removed from the extracted substance, which is powdered to give a tea extract. Baby powder is mixed with preferably 0.05-10% of the tea extract to give a baby powder composition. A mixture of 95-98% of talc, 1-5% of an antiseptic and a proper amount of an aromatic substance is preferable as the baby powder. The baby powder absorbs sweat from skin, prevents chapped skin, keeps skin smooth and has deodorizing effect on body smell. Since these teas are naturally-occurring substances, they are safe even in contact with skin and are inexpensive.
PURPOSE: To obtain a retinoid compd. which has a phospholipase A 2  inhibiting activity and is useful for the treatment of inflammatory diseases.  
     CONSTITUTION: This compd. is expressed by formula I. In formula I, R 1  is CH=CY-C(CH 3 )=CHX (X, Y are each CO 2 R', expressed by formula II, R' and R" are each H or a 1 to 6 C alkyl), and R 1  includes all possible geometric isomers. This compd. can be synthesized by a well-known method. A pharmaceutical compsn. is obtd. by incorporating the compd. expressed by formula I as an effective component by 0.005 10 wt.%, and mixing with a pharmaceutically allowed carrier to produce a drug. The compsn. can be produced in forms of a lotion, cream, gel tablet and elixir, and as for an oral medicine, the compsn. is medicated daily by 0.1 to 50 mg/kg. The drug is effective for treatments not only of arthritis, inflammatory intestinal disorder and overt inflammation but inflammation of an eye structure. 
     COPYRIGHT: (C)1992,JPO
Background: Coronavirus pandemic health restrictions has deleteriously affected the rates of all interventional procedures even for emergency cases. This study tried to evaluate the impact of the outbreak of SARS-CoV-19 infection on rates of interventional pain therapy (IPT).

Methods: Setting: Multicenter Study. Design: Prospective observational study, approved by the Local Ethical Committee (RC:2-1-21). Materials: Two 20-item questionnaires with five choices for probable answer using a Likert-5 point scale were constructed as self-assessment questionnaire. The questionnaires were uploaded to the Google drive, and the links and identification codes were sent using the WhatsApp to 500 IPT providers. The feedback answers were scored and statistically analyzed. Statistical analyses will be performed using IBM® SPSS® Statistics (Version 22, 2015; Armonk, USA) for Windows statistical package. P value \<0.05 was considered statistically significant.